Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 5/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29716744 | 1.00 | KMT2A (0.55) | KMT2ATLR2MDM2FOLH1TLR1 | |
| SCHEMBL31584148 | 0.93 | TLR2 (0.57) | KMT2ATLR2MDM2 | |
| SCHEMBL22408647 | 0.93 | TLR2 (0.57) | KMT2ATLR2MDM2 | |
| SCHEMBL21222814 | 0.93 | TLR2 (0.57) | KMT2ATLR2MDM2 | |
| SCHEMBL22408648 | 0.93 | TLR2 (0.57) | KMT2ATLR2MDM2 | |
| SCHEMBL31259011 | 0.93 | TLR2 (0.57) | KMT2ATLR2MDM2 | |
| SCHEMBL21222782 | 0.93 | TLR2 (0.57) | KMT2ATLR2MDM2 | |
| SCHEMBL22654312 | 0.93 | TLR2 (0.57) | KMT2ATLR2MDM2 | |
| SCHEMBL21223782 | 0.93 | TLR2 (0.57) | KMT2ATLR2MDM2 | |
| SCHEMBL18171056 | 0.93 | TLR2 (0.57) | KMT2ATLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| EP-4514396-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023208216-A9 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-08-29 | — | — | WO | disclosed |
| WO-2023208216-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | TOP1, TOP2A, TOP2B | KMT2A 980/4885TLR2 2865/4885MDM2 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.